Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Brain : a Journal of Neurology|October 3, 2006
Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurologyS Vucic, D Tian, P Siao Tick Chong, et al.Neurology|July 13, 2006
Neuroprotective agents for clinical trials in ALS: a systematic assessmentB J Traynor, L Bruijn, R Conwit, et al.Neurology|February 9, 2005
Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relativesA J Steele, A Al-Chalabi, K Ferrante, et al.Neurology|May 5, 1999
The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosisM E Cudkowicz, P M Sexton, T Ellis, et al.Journal of the Neurological Sciences|March 5, 2003
Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseasesS Lorenzl, D S Albers, P A LeWitt, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|January 1, 1997
Altered fractal dynamics of gait: reduced stride-interval correlations with aging and Huntington's diseaseJ M Hausdorff, S L Mitchell, R Firtion, et al.Movement Disorders : Official Journal of the Movement Disorder Society|March 26, 1999
Riluzole therapy in Huntington's disease (HD)H D Rosas, W J Koroshetz, B G Jenkins, et al.Neurology|November 28, 2001
Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutationsJ M Shefner, R H Brown, D Cole, et al.Neurology|March 19, 2008
Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALSA-M Wills, J E Landers, H Zhang, et al.Neurology|July 1, 1997
Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic studyM E Cudkowicz, L Warren, J W Francis, et al.Pageof 3